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This supplement of the Journal of Neurology corre-
sponds to the proceedings ofan MS Experts Boardmeet-
ing entitled ‘New insights into the pathology of multiple
sclerosis’held in Barcelona,Spain on June 24,2006.Dur-
ing the meeting, the latest research related to the basic
mechanisms underlying myelin and axonal damage and
repair in multiple sclerosis was reviewed, as well as the
consequences of this for characterising new therapeutic
strategies aimed at facilitating immunological protec-
tion and enhancing repair.
Wolfgang Brück (Göttingen,Germany) addressed the
relationship between inflammation and neurodegener-
ation in disease development. These two processes are
closely interconnected from the earliest stages of dis-
ease, but their relative contribution may vary between
individuals, between disease stages and even between
individual lesions. Current knowledge is insufficient to
bring together these two aspects of pathophysiology
into a unified hypothesis of disease,which remains nev-
ertheless a major goal for multiple sclerosis research.
Lloyd Kasper (Dartmouth,USA) described the role of
T regulatory cells in immune homeostasis, and how
their activity can be harnessed to prevent,or attenuate,
the emergence of autoimmune disease.He presented ev-
idence that glatiramer acetate could stimulate the prolif-
eration and activity of T regulatory cells and suggested
that these effects could contribute to its beneficial ther-
apeutic effects in multiple sclerosis.
The failure of remyelination in multiple sclerosis and
strategies for promoting remyelination were reviewed
from a developmental perspective by Charles ffrench-
Constant (Cambridge, UK). He described the complex
interplay of humoral and matrix factors that influence
proliferation, differentiation and maturation of oligo-
dendrocyte precursor cells,which represents a challeng-
ing target for the development of treatments aimed at
promoting remyelination.
Gianvito Martino (Milan, Italy) evoked the promise
of neural precursor cell therapy for limiting neuronal
damage and promoting repair in multiple sclerosis.Re-
cent research has shown that such cells can be isolated
from adult mice and inoculated into host mice where
they infiltrate the nervous system, target sites of tissue
damage and promote neuronal repair through a palette
of bystander effects.
Martin Kerschensteiner (Munich, Germany) dis-
cussed the mechanisms whereby neural circuits in the
spinal cord can be remodelled following spinal injury.
This previously unexpected degree ofplasticity is an im-
portant determinant of functional recovery after de-
myelinating or traumatic injury. The development of
therapies to facilitate this remodelling represents a
promising avenue of research for rehabilitation follow-
ing spinal injury.
Neurotrophic factors may play an important role in
limiting neuronal damage and promoting repair in mul-
tiple sclerosis, and inducing their secretion or activity
may be of great interest in treatment. Ralf Gold
(Bochum, Germany) reviewed the data on growth fac-
tors in multiple sclerosis with particular emphasis on
BDNF,CNTF and LIF.He described how release of neu-
rotrophins from immune cells infiltrating lesions in
multiple sclerosis may contribute to neuronal repair,
and indicated that facilitating neurotrophin release
would be a potentially useful therapeutic strategy.
The consequences of treatment with glatiramer ac-
etate on repair mechanisms in multiple sclerosis were
reviewed by Ruth Arnon (Rehovot,Israel),with particu-
lar reference to the rodent experimental autoimmune
encephalomyelitis model. Glatiramer acetate treatment
generates a specific population of T cells in the periph-
ery which enter the brain. Here, they target lesions and
release anti-inflammatory cytokines to suppress inflam-
mation and BDNF, which protects axons and neuronal
cell bodies from damage caused by inflammation or de-
myelination, as well as promoting proliferation, migra-
tion and maturation of neural progenitor cells at sites of
tissue injury.
The potentially beneficial effects of inflammation 
in multiple sclerosis were discussed by Reinhard
Hohlfeld (Munich, Germany), who described how im-
mune cells infiltrating the nervous system during in-
flammatory flares can release a variety of trophic factors
which allow a dynamic interaction between the nervous
and immune systems.This underlies the concept of neu-
roprotective autoimmunity. Harnessing the beneficial
effects of inflammation represents a promising thera-
peutic approach to improving treatment of multiple
sclerosis.
Finally, Massimo Filippi (Milan, Italy) reviewed the
different magnetic resonance (MR) imaging techniques
and tools which can be used to monitor the disease
process in multiple sclerosis and possibly to distinguish
between damage and repair mechanisms.He described
how the development of non-conventional MR imaging
techniques such as magnetization transfer, diffusion
tensor imaging, functional MRI and MR spectroscopy
has been critical for demonstrating neurodegenerative
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activity from the earliest stages of disease and for visu-
alising potential neuroprotective effects of treatments.
The ideas discussed in the symposium revealed the
vitality of research into the pathology of multiple scle-
rosis, with many new concepts and fields of research,
such as the control of oligodendrocytogenesis, neuro-
protective autoimmunity, immune system homeostasis
and the properties of adult neural precursor cells. Ex-
ploitation of these different novel biological mecha-
nisms represents so many perspectives for improved
treatment of multiple sclerosis. We hope that this sup-
plement of the Journal of Neurologywill provide readers
with an overview of these exciting new developments
and stimulate further research to improve the treatment
of multiple sclerosis.
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